Jennison Associates LLC Purchases 937,204 Shares of Eli Lilly and Company $LLY

Key Points

• Jennison Associates LLC increased its LLY stake by 22.3%, buying 937,204 shares to hold 5,133,676 shares (about 0.54% of Eli Lilly), a position valued at roughly $5.52 billion and representing ~3.3% of Jennison’s portfolio (its 7th largest holding).
• Eli Lilly beat expectations in Q1 with $19.8 billion revenue and $8.55 EPS (vs. $6.97 consensus) and raised FY2026 guidance to $82–85B revenue and $35.50–37 EPS, prompting analyst upgrades and higher price targets.
• Operationally, Lilly’s oral GLP‑1 Foundayo has shown early traction (>20,000 patients) and the FDA’s proposal to limit compounding could protect branded pricing, but competition (Novo’s oral rollout), PBM/insurer pressure and compounding/generic risks remain key downside factors.

Jennison Associates LLC increased its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 22.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,133,676 shares of the company's stock after acquiring an additional 937,204 shares during the quarter. Eli Lilly and Company comprises about 3.3% of Jennison Associates LLC's investment portfolio, making the stock its 7th largest position. Jennison Associates LLC owned approximately 0.54% of Eli Lilly and Company worth $5,517,059,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in LLY. Brighton Jones LLC increased its holdings in Eli Lilly and Company by 22.0% in the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock valued at $7,409,000 after purchasing an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC increased its holdings in Eli Lilly and Company by 2.8% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company's stock valued at $1,136,000 after purchasing an additional 40 shares during the last quarter. Schnieders Capital Management LLC. increased its holdings in Eli Lilly and Company by 16.7% in the second quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company's stock valued at $6,231,000 after purchasing an additional 1,141 shares during the last quarter. Flow Traders U.S. LLC bought a new stake in Eli Lilly and Company in the second quarter valued at about $356,000. Finally, Nebula Research & Development LLC bought a new stake in Eli Lilly and Company in the second quarter valued at about $749,000. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q1 results and guidance boost: Lilly reported roughly $19.8B revenue and $8.55 non‑GAAP EPS (well above consensus), raised 2026 revenue guidance to $82–85B and lifted EPS guidance to $35.50–37 — a primary driver of the rally. Eli Lilly raises annual profit forecast as GLP-1 drugs fuel growth
• Positive Sentiment: Foundayo (oral GLP‑1) early traction: Foundayo — the first oral GLP‑1 with no food/water timing restrictions — has seen early prescriptions (management cites >20,000 patients), supporting longer‑term market share and convenience advantages versus rivals. Lilly's Double-Beat Widens the GLP-1 Gap—And a New Pill Could Make It Permanent
• Positive Sentiment: Regulatory tailwind for pricing/protection: The FDA proposed excluding key GLP‑1 active ingredients from the compounding bulk list — a move that would limit cheaper mass compounding and help protect branded volumes/pricing. US FDA proposes excluding weight-loss drugs from compounding list
• Positive Sentiment: Street upgrades and higher price targets: Major banks raised price targets and reiterated buy/overweight ratings after the results and guidance, supporting momentum from institutional analysts. Cantor Fitzgerald raises PT
• Neutral Sentiment: Novo’s oral rollout increases scrutiny: Novo Nordisk is expanding its oral GLP‑1 presence (rebranded Rybelsus/Ozempic pills across many pharmacies), a development investors will watch but which hasn’t flipped the narrative away from Lilly yet. Novo Launches Ozempic Pills Across 70,000 US Pharmacies
• Neutral Sentiment: Valuation and long‑term upside debate: Several analyses highlight a tension between Lilly’s strong top‑line growth and a stretched valuation after multi‑year gains; some see material upside if GLP‑1 momentum persists, others caution about multiple compression risk. Eli Lilly Stock’s Path To 30% Upside
• Negative Sentiment: Competitive and pricing pressure risks remain: PBM/insurer negotiation, faster ramps from rivals and longer‑term generic/compounding threats could pressure realized prices and margin expansion — a risk highlighted in market commentary despite the quarter’s beat. Fast Money panel on Novo vs Lilly
• Negative Sentiment: Regulatory / stakeholder friction: Hospital groups have pushed back on certain Lilly data/340B requests, which could create policy or reimbursement friction to monitor. AHA urges HHS to block Lilly 340B data demands

Analyst Ratings Changes

LLY has been the subject of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft reiterated a "buy" rating and issued a $1,285.00 price objective on shares of Eli Lilly and Company in a report on Friday, March 6th. Wall Street Zen upgraded Eli Lilly and Company from a "buy" rating to a "strong-buy" rating in a report on Saturday. UBS Group reiterated a "buy" rating on shares of Eli Lilly and Company in a report on Wednesday, March 18th. Weiss Ratings reiterated a "buy (b)" rating on shares of Eli Lilly and Company in a report on Friday, March 27th. Finally, Jefferies Financial Group set a $1,300.00 price objective on Eli Lilly and Company and gave the company a "buy" rating in a report on Friday, March 13th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $1,212.96.

Eli Lilly and Company Stock Up 0.2%

Shares of Eli Lilly and Company stock opened at $965.19 on Monday. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,133.95. The business has a 50-day moving average of $947.05 and a two-hundred day moving average of $987.36. The company has a market capitalization of $911.93 billion, a P/E ratio of 34.29, a price-to-earnings-growth ratio of 1.13 and a beta of 0.48. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. During the same period in the prior year, the company earned $3.34 earnings per share. The company's revenue for the quarter was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, equities analysts predict that Eli Lilly and Company will post 33.79 EPS for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.